145 related articles for article (PubMed ID: 24008428)
21. Intrathecal administration of the cannabinoid 2 receptor agonist JWH015 can attenuate cancer pain and decrease mRNA expression of the 2B subunit of N-methyl-D-aspartic acid.
Gu X; Mei F; Liu Y; Zhang R; Zhang J; Ma Z
Anesth Analg; 2011 Aug; 113(2):405-11. PubMed ID: 21519057
[TBL] [Abstract][Full Text] [Related]
22. Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury.
Brownjohn PW; Ashton JC
Neuroscience; 2012 Feb; 203():180-93. PubMed ID: 22210507
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling.
Franklin JM; Carrasco GA
Synapse; 2013 Mar; 67(3):145-59. PubMed ID: 23151877
[TBL] [Abstract][Full Text] [Related]
24. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells.
Cianchi F; Papucci L; Schiavone N; Lulli M; Magnelli L; Vinci MC; Messerini L; Manera C; Ronconi E; Romagnani P; Donnini M; Perigli G; Trallori G; Tanganelli E; Capaccioli S; Masini E
Clin Cancer Res; 2008 Dec; 14(23):7691-700. PubMed ID: 19047095
[TBL] [Abstract][Full Text] [Related]
25. A Single Intrathecal or Intraperitoneal Injection of CB2 Receptor Agonist Attenuates Bone Cancer Pain and Induces a Time-Dependent Modification of GRK2.
Lu C; Shi L; Sun B; Zhang Y; Hou B; Sun Y; Ma Z; Gu X
Cell Mol Neurobiol; 2017 Jan; 37(1):101-109. PubMed ID: 26935064
[TBL] [Abstract][Full Text] [Related]
26. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro.
Harvey BS; Ohlsson KS; Mååg JL; Musgrave IF; Smid SD
Neurotoxicology; 2012 Jan; 33(1):138-46. PubMed ID: 22233683
[TBL] [Abstract][Full Text] [Related]
27. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
Beltramo M; Bernardini N; Bertorelli R; Campanella M; Nicolussi E; Fredduzzi S; Reggiani A
Eur J Neurosci; 2006 Mar; 23(6):1530-8. PubMed ID: 16553616
[TBL] [Abstract][Full Text] [Related]
28. Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation.
Gustafsson K; Wang X; Severa D; Eriksson M; Kimby E; Merup M; Christensson B; Flygare J; Sander B
Int J Cancer; 2008 Sep; 123(5):1025-33. PubMed ID: 18546271
[TBL] [Abstract][Full Text] [Related]
29. Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts.
Lépicier P; Lagneux C; Sirois MG; Lamontagne D
Life Sci; 2007 Oct; 81(17-18):1373-80. PubMed ID: 17931662
[TBL] [Abstract][Full Text] [Related]
30. Effect of CP55,940 on mechanosensory spinal neurons following chronic inflammation.
Choong KC; Su X; Urban MO
Neurosci Lett; 2007 Mar; 414(2):105-9. PubMed ID: 17194542
[TBL] [Abstract][Full Text] [Related]
31. Spinal cannabinoid CB1 or CB2 receptors activation attenuates mechanical allodynia in streptozotocin-induced diabetic rats.
Gonçalves MR; da Conceição MS; Jesus CHA; Gasparin AT; Rosa ES; da Cunha JM
Behav Pharmacol; 2022 Apr; 33(2&3):158-164. PubMed ID: 32804775
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoid receptors in conjunctival epithelium: identification and functional properties.
Iribarne M; Torbidoni V; Julián K; Prestifilippo JP; Sinha D; Rettori V; Berra A; Suburo AM
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4535-44. PubMed ID: 18566465
[TBL] [Abstract][Full Text] [Related]
34. Antihyperalgesic effect of CB
Oliveira-Fusaro MCG; Zanoni CIS; Dos Santos GG; Manzo LP; Araldi D; Bonet IJM; Tambeli CH; Dias EV; Parada CA
Eur J Pharmacol; 2017 Mar; 798():113-121. PubMed ID: 28131783
[TBL] [Abstract][Full Text] [Related]
35. Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy.
Bujalska M
Pharmacology; 2008; 82(3):193-200. PubMed ID: 18810243
[TBL] [Abstract][Full Text] [Related]
36. Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation.
Zeng F; Wade A; Harbert K; Patel S; Holley JS; Dehghanpuor CK; Hopwood T; Marino S; Sophocleous A; Idris AI
Sci Rep; 2024 Mar; 14(1):5782. PubMed ID: 38461339
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats.
Merriam FV; Wang ZY; Guerios SD; Bjorling DE
Neurosci Lett; 2008 Nov; 445(1):130-4. PubMed ID: 18778751
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of cannabinoid receptor ligands: current status.
Singh J; Budhiraja S
Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoid receptor 2‑selective agonist JWH015 attenuates bone cancer pain through the amelioration of impaired autophagy flux induced by inflammatory mediators in the spinal cord.
Mao Y; Huang Y; Zhang Y; Wang C; Wu H; Tian X; Liu Y; Hou B; Liang Y; Rong H; Gu X; Ma Z
Mol Med Rep; 2019 Dec; 20(6):5100-5110. PubMed ID: 31661120
[TBL] [Abstract][Full Text] [Related]
40. Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.
Fu W; Taylor BK
Neurosci Lett; 2015 May; 595():1-6. PubMed ID: 25849525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
